Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension

V. McLaughlin, RN. Channick, HA. Ghofrani, JC. Lemarié, R. Naeije, M. Packer, R. Souza, VF. Tapson, J. Tolson, H. Al Hiti, G. Meyer, MM. Hoeper,

. 2015 ; 46 (2) : 405-13. [pub] 20150625

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020630

The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (≥20 mg three times daily) for ≥3 months were randomised (1:1) to placebo or bosentan (125 mg twice daily). The composite primary end-point was the time to the first morbidity/mortality event, defined as all-cause death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH worsening. Secondary/exploratory end-points included change in 6-min walk distance and World Health Organization functional class at 16 weeks, change in N-terminal pro-brain natriuretic peptide (NT-proBNP) over time, and all-cause death.Overall, 334 PAH patients were randomised to placebo (n=175) or bosentan (n=159). A primary end-point event occurred in 51.4% of patients randomised to placebo and 42.8% to bosentan (hazard ratio 0.83, 97.31% CI 0.58-1.19; p=0.2508). The mean between-treatment difference in 6-min walk distance at 16 weeks was +21.8 m (95% CI +5.9-37.8 m; p=0.0106). Except for NT-proBNP, no difference was observed for any other end-point. The safety profile of bosentan added to sildenafil was consistent with the known bosentan safety profile.In COMPASS-2, adding bosentan to stable sildenafil therapy was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality event.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020630
003      
CZ-PrNML
005      
20160805112354.0
007      
ta
008      
160722s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1183/13993003.02044-2014 $2 doi
024    7_
$a 10.1183/13993003.02044-2014 $2 doi
035    __
$a (PubMed)26113687
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a McLaughlin, Vallerie $u Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA vmclaugh@umich.edu.
245    10
$a Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension / $c V. McLaughlin, RN. Channick, HA. Ghofrani, JC. Lemarié, R. Naeije, M. Packer, R. Souza, VF. Tapson, J. Tolson, H. Al Hiti, G. Meyer, MM. Hoeper,
520    9_
$a The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (≥20 mg three times daily) for ≥3 months were randomised (1:1) to placebo or bosentan (125 mg twice daily). The composite primary end-point was the time to the first morbidity/mortality event, defined as all-cause death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH worsening. Secondary/exploratory end-points included change in 6-min walk distance and World Health Organization functional class at 16 weeks, change in N-terminal pro-brain natriuretic peptide (NT-proBNP) over time, and all-cause death.Overall, 334 PAH patients were randomised to placebo (n=175) or bosentan (n=159). A primary end-point event occurred in 51.4% of patients randomised to placebo and 42.8% to bosentan (hazard ratio 0.83, 97.31% CI 0.58-1.19; p=0.2508). The mean between-treatment difference in 6-min walk distance at 16 weeks was +21.8 m (95% CI +5.9-37.8 m; p=0.0106). Except for NT-proBNP, no difference was observed for any other end-point. The safety profile of bosentan added to sildenafil was consistent with the known bosentan safety profile.In COMPASS-2, adding bosentan to stable sildenafil therapy was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality event.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antihypertenziva $x aplikace a dávkování $x terapeutické užití $7 D000959
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x farmakoterapie $7 D006976
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a sildenafil citrát $x aplikace a dávkování $x terapeutické užití $7 D000068677
650    _2
$a sulfonamidy $x aplikace a dávkování $x terapeutické užití $7 D013449
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vazodilatancia $x aplikace a dávkování $x terapeutické užití $7 D014665
651    _2
$a Švýcarsko $7 D013557
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Channick, Richard N $u Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA.
700    1_
$a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center, Giessen, Germany.
700    1_
$a Lemarié, Jean-Christophe $u Department of Statistics, Effi-Stat, Paris, France.
700    1_
$a Naeije, Robert $u Department of Cardiology, Erasme University Hospital, Brussels, Belgium.
700    1_
$a Packer, Milton $u Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
700    1_
$a Souza, Rogério $u Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
700    1_
$a Tapson, Victor F $u Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
700    1_
$a Tolson, Jonathan $u Global Medical Affairs, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Al Hiti, Hikmet $u Department of Cardiology, IKEM, Prague, Czech Republic. $7 gn_A_00003146
700    1_
$a Meyer, Gisela $u Complexo Hospitalar Santa Casa De Porto Alegre, Pulmonary Vascular Research Institute, Porto Alegre, Brazil.
700    1_
$a Hoeper, Marius M $u Department of Respiratory Medicine, Hannover Medical School and German Center of Lung Research (DZL), Hannover, Germany.
773    0_
$w MED00001660 $t The European respiratory journal $x 1399-3003 $g Roč. 46, č. 2 (2015), s. 405-13
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26113687 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160805112627 $b ABA008
999    __
$a ok $b bmc $g 1155300 $s 945158
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 46 $c 2 $d 405-13 $e 20150625 $i 1399-3003 $m The European respiratory journal $n Eur Respir J $x MED00001660
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace